News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
STAMFORD, Conn. , July 29, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
STAMFORD, Conn. , July 24, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics Announces Proposed Offering of Common Stock
STAMFORD, Conn. , July 24, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
- Study now fully enrolled; topline data expected in 4Q 2019 - STAMFORD, Conn. , July 22, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively
View HTML
Toggle Summary Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
STAMFORD, Conn. , July 09, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Completed Phase 1 trial in patients with hepatic impairment established Oral KORSUVA tablet strength STAMFORD, Conn., June 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to
View HTML
Toggle Summary Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
STAMFORD, Conn. , May 31, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML
Toggle Summary Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) – - Statistically significant improvement in key secondary endpoint of proportion of patients with four
View HTML
Toggle Summary Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
STAMFORD, Conn. , May 08, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML
Toggle Summary Cara Therapeutics Reports First Quarter 2019 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , May 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting
View HTML